Author
Terry Robinson
Respiratory Nurse - Consultant Harrogate and District NHS Foundation Trust
Introduction
Chronic obstructive pulmonary disease (COPD) affects up to three million people in the UK. Sputum production is a common feature of COPD but for some patients it is difficult to clear, leaving them potentially vulnerable to respiratory infections. This article looks at the evidence for mucolytic therapies and when they should be considered.
